Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients
Status:
Completed
Trial end date:
2020-11-09
Target enrollment:
Participant gender:
Summary
This is a multi-center, first-in-human, open-label, Phase 1/2A dose-escalation study in which
eligible patients with metastatic castration-resistant prostate carcinoma (mCRPC) will
receive oral doses of TRC253. The study will be conducted in 2 parts: part 1 (dose
escalation) and part 2 (dose expansion).